Children's Hospital of Philadelphia leads or participates in hundreds of clinical trials. Use this database to learn the purpose of these trials, find out who can participate and more.
121 - 124 of 124
Prospective data collection will be conducted at CHOP and includes a series of questionnaires and a medical record review including information collected at normally scheduled clinic follow-up visits. Subjects will also participate in study testing at regularly scheduled clinic follow-up visits. This testing will include tests of muscle strength and walking ability,
The purpose of this research study is to collect information over time in juvenile SpA and back pain patients. The information from this study will be used to better understand these conditions in children as well as improve treatment guidelines. The procedures include questionnaires, medical record review, and optional biospecimen contributions (blood and urine).
This is an observational registry of children and young adults with pediatric-onset rheumatic conditions such as juvenile idiopathic arthritis (JIA) and Systemic Lupus Erythematosus (SLE) and SLE-like conditions. The registry will be used to answer questions about how safe medications are, how well medications work, and how well patients do over time. Patients who agree to participate will allow their health information to be used for research, complete a brief questionnaire during their clinic visits, and in some cases, be asked to give a sample of blood, urine, cheek swabs, stool, leftover (from clinical procedure) joint fluid, and leftover (from clinical procedure) tissue biopsy.
The Alterra study is for patients in need of pulmonary valve replacement. The Alterra Adaptive Prestent is a transcatheter stent designed for patients in need of a pulmonary valve replacement who do not want to have to undergo surgery, but have a pulmonary artery poorly suited for current approved transcatheter valves. Surgical placement of a new valve is the most common treatment for a nonworking pulmonary valve, however, there are many risks associated with open heart surgery and it is followed by months of recovery. We are conducting this study to see whether there is a less invasive approach by placing and Alterra Adaptive Prestent to make the pulmonary artery appropriate for transcatheter valve replacement. The Alterra Adaptive Prestent has not been approved by the FDA yet for commercial use and is only available by participating in the study. Please contact Dr. Matthew Gillespie (email@example.com) if you or your patient may be interested in participating in the trial of this device.